Altizem

1⃣ objectif commun 👉 grandir ensemble! ➖ #CRO & #ingénierie, spécialiste de la #santé, #pharmaceutique, #dispositifsmédicaux, #agroalimentaire, #cosmétique !

[Altizem @AltiTeam]

Nous sommes (très) fiers de vous annoncer notre accréditation ImpactIndex® 2021 ! #Altizem #ChooseMyCompany #Label #2021

[Altizem @AltiTeam]

Nous sommes (très) fiers de vous annoncer notre accréditation ImpactIndex® 2021 ! #deveniraltizien #ChooseMyCompany #Label #2021

[Université Paris Cité @univ_paris_cite]

🔎 #Covid19 : découverte des mécanismes de la perte de l’odorat !
Des chercheurs de @institutpasteur @univ_paris @cnrs @inserm et @aphp, ont élucidé les mécanismes impliqués dans la perte d’odorat chez les patients infectés par le SARS-CoV-2.
➡️https://t.co/zUZWE0V02u

[Altizem @AltiTeam]

"A new research project, announced by the UK’s Drug Safety Research Unit (DSRU), will aim to improve understanding of differing decisions on medicine use between different countries and regions."

https://t.co/eBWebQq7Jx

[Industrie Pharma Magazine @IPM_Pharma]

Covid-19 : AstraZeneca défend son vaccin avec de nouvelles données https://t.co/q5GekJIw9T #COVID19

[Altizem @AltiTeam]

[news] 📰

"In the Phase I trial, the beta-2 adrenoceptor agonist salbutamol significantly increased cerebral perfusion, a key biomarker in neurodegenerative disease."

https://t.co/2K0qPHb7fF

[Altizem @AltiTeam]

[news] 📰

"La société grenobloise @SleepInnov a dévoilé au début de l'année son dernier appareil connecté, doté d'intelligence artificielle (IA) et "design", intitulé Haloa."

https://t.co/Sk0Ikoh7FX

[European Pharmaceutical Review @PharmaReview]

The FDA has approved emergency use of the PCR based Alinity™ m Resp-4-Plex molecular assay which can detect SARS-CoV-2, #influenza A, influenza B and respiratory syncytial #virus (RSV).
#Covid19 #diagnostics #assays #pharma
Read on: https://t.co/spXT1DuKBL

[Altizem @AltiTeam]

[news] 📰

Novartis Gene Therapies’ Zolgensma (onasemnogene abeparvovec) will be available for use in the UK’s National Health Services, Inc (NHS) following recommendations by regulators in England and Wales, as well as Scotland.

#pharma #uk

https://t.co/NlJQx7dbwf

[ONU Femmes @ONUFemmes]

Mettons fin au silence.
Mettons fin aux stéréotypes.
Mettons fin aux discriminations.
Mettons fin aux normes de genre.
Mettons fin aux obstacles systématiques.
Faisons de l’égalité femmes-hommes une réalité avec la #GénérationÉgalité.

#JourneeDesDroitsDesFemmes #IWD2021

[Altizem @AltiTeam]

[news] 📰

"Sanofi and GSK are set to begin a new Phase II study of their #COVID-19, after a delay to the programme was announced in December 2020."

https://t.co/6W42esqFL5

[Industrie Pharma Magazine @IPM_Pharma]

GSK et Vir Biotechnology étendent leur partenariat https://t.co/slRWdAmw0g

[Altizem @AltiTeam]

[news] 📰

" ONK Therapeutics has announced a new collaboration with blood cancer charity Antony Nolan, with the aim of accelerating the development of next-generation natural killer (NK) cell therapies."

https://t.co/RcuzCqjoKY

[European Pharmaceutical Review @PharmaReview]

Exploring the use of #disaccharide excipients for stabilising #biologics and making recommendations for enhancing supply chain security https://t.co/m3K86c0V9Q

[Altizem @AltiTeam]

[news] 📰

"The European Commission has approved Celltrion Healthcare Co.,Ltd. 's Yuflyma, a biosimilar to adalimumab – marketed by AbbVie as Humira."

https://t.co/55sYVlTVsh

[Altizem @AltiTeam]

[news] 📰

"@MindMed, a leading psychedelic medicine biotech company announced another partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties."

https://t.co/oT1idKpzXg

[Altizem @AltiTeam]

[news] 📰
"The European Commission (EC) has approved the expanded use of Janssen’s Spravato for the rapid reduction of depressive symptoms in a psychiatric emergency, for adult patients with a moderate-to-severe episode of major depressive disorder (MDD)."
https://t.co/aUxhiUXsvy

[European Pharmaceutical Review @PharmaReview]

Breyanzi (lisocabtagene maraleucel) was approved on the 54 percent complete remission rate achieved in diffuse large B-cell #lymphoma trials.
#clinicaltrials #oncology #genetherapy #Tcells
Read the news: https://t.co/4TU5G45IDV

[Altizem @AltiTeam]

[news] 📰
Un consortium mené par Owkin présente un outil d'IA pour prédire la gravité du #COVID19
#innovation

https://t.co/TlNVoNdpQN

[Altizem @AltiTeam]

Alti'day : c'est la Chandeleur !
Selon la légende païenne, il s’agit du jour de la célébration de l’allongement de la durée du jour, où les crêpes symbolisent le soleil. 🌞
(Chez Altizem, on trouve que c’est surtout une bonne excuse pour un bon goûter ! 😛)

#altiteam